ERB-041

DRUG6 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Crohn's DiseaseCystitis, InterstitialDysmenorrheaDyspareuniaEndometriosisHealthyLong QT SyndromePelvic Pain

Phase 1

Study Evaluating ERB-041 in Active Crohn's Disease

CompletedNCT00245947

Wyeth is now a wholly owned subsidiary of PfizerCrohn's Disease

Start: 2004-04-30End: 2005-04-30Updated: 2009-09-10

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

CompletedNCT00316459

Wyeth is now a wholly owned subsidiary of PfizerHealthy, Long QT Syndrome

Start: 2006-05-31Target: 64Updated: 2007-04-13

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

CompletedNCT00434187

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2006-08-31End: 2006-10-31Target: 24Updated: 2009-07-10

Phase 2

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

CompletedNCT00110487

Wyeth is now a wholly owned subsidiary of PfizerEndometriosis

Start: 2005-01-31End: 2006-12-31Target: 200Updated: 2015-05-01

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

CompletedNCT00318500

Wyeth is now a wholly owned subsidiary of PfizerDysmenorrhea, Dyspareunia, Endometriosis +1

Start: 2006-05-31End: 2006-12-31Target: 150Updated: 2007-12-10

Unknown Phase

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

WithdrawnNCT00275379

Wyeth is now a wholly owned subsidiary of PfizerCystitis, Interstitial

Start: 2006-08-31Updated: 2020-10-01